TY - JOUR
T1 - Pulmonary microbiome and gene expression signatures differentiate lung function in pediatric hematopoietic cell transplant candidates
AU - Zinter, Matt S.
AU - Versluys, A. Birgitta
AU - Lindemans, Caroline A.
AU - Mayday, Madeline Y.
AU - Reyes, Gustavo
AU - Sunshine, Sara
AU - Chan, Marilynn
AU - Fiorino, Elizabeth K.
AU - Cancio, Maria
AU - Prevaes, Sabine
AU - Sirota, Marina
AU - Matthay, Michael A.
AU - Kharbanda, Sandhya
AU - Dvorak, Christopher C.
AU - Boelens, Jaap J.
AU - DeRisi, Joseph L.
N1 - Publisher Copyright:
© 2022 The Authors.
PY - 2022/3/9
Y1 - 2022/3/9
N2 - Impaired baseline lung function is associated with mortality after pediatric allogeneic hematopoietic cell transplantation (HCT), yet limited knowledge of the molecular pathways that characterize pretransplant lung function has hindered the development of lung-targeted interventions. In this study, we quantified the association between bronchoalveolar lavage (BAL) metatranscriptomes and paired pulmonary function tests performed a median of 1 to 2 weeks before allogeneic HCT in 104 children in The Netherlands. Abnormal pulmonary function was recorded in more than half the cohort, consisted most commonly of restriction and impaired diffusion, and was associated with both all-cause and lung injury-related mortality after HCT. Depletion of commensal supraglottic taxa, such as Haemophilus, and enrichment of nasal and skin taxa, such as Staphylococcus, in the BAL microbiome were associated with worse measures of lung capacity and gas diffusion. In addition, BAL gene expression signatures of alveolar epithelial activation, epithelial-mesenchymal transition, and down-regulated immunity were associated with impaired lung capacity and diffusion, suggesting a postinjury profibrotic response. Detection of microbial depletion and abnormal epithelial gene expression in BAL enhanced the prognostic utility of pre-HCT pulmonary function tests for the outcome of post-HCT mortality. These findings suggest a potentially actionable connection between microbiome depletion, alveolar injury, and pulmonary fibrosis in the pathogenesis of pre- HCT lung dysfunction.
AB - Impaired baseline lung function is associated with mortality after pediatric allogeneic hematopoietic cell transplantation (HCT), yet limited knowledge of the molecular pathways that characterize pretransplant lung function has hindered the development of lung-targeted interventions. In this study, we quantified the association between bronchoalveolar lavage (BAL) metatranscriptomes and paired pulmonary function tests performed a median of 1 to 2 weeks before allogeneic HCT in 104 children in The Netherlands. Abnormal pulmonary function was recorded in more than half the cohort, consisted most commonly of restriction and impaired diffusion, and was associated with both all-cause and lung injury-related mortality after HCT. Depletion of commensal supraglottic taxa, such as Haemophilus, and enrichment of nasal and skin taxa, such as Staphylococcus, in the BAL microbiome were associated with worse measures of lung capacity and gas diffusion. In addition, BAL gene expression signatures of alveolar epithelial activation, epithelial-mesenchymal transition, and down-regulated immunity were associated with impaired lung capacity and diffusion, suggesting a postinjury profibrotic response. Detection of microbial depletion and abnormal epithelial gene expression in BAL enhanced the prognostic utility of pre-HCT pulmonary function tests for the outcome of post-HCT mortality. These findings suggest a potentially actionable connection between microbiome depletion, alveolar injury, and pulmonary fibrosis in the pathogenesis of pre- HCT lung dysfunction.
KW - Child
KW - Hematopoietic Stem Cell Transplantation
KW - Humans
KW - Lung/metabolism
KW - Microbiota/genetics
KW - Pulmonary Fibrosis
KW - Transcriptome/genetics
UR - http://www.scopus.com/inward/record.url?scp=85126171812&partnerID=8YFLogxK
U2 - 10.1126/scitranslmed.abm8646
DO - 10.1126/scitranslmed.abm8646
M3 - Article
C2 - 35263147
AN - SCOPUS:85126171812
SN - 1946-6234
VL - 14
SP - eabm8646
JO - Science Translational Medicine
JF - Science Translational Medicine
IS - 635
M1 - abm8646
ER -